Concepedia

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette, Sophie Piperno‐Neumann, Nicolas Penel, Emmanuelle Bompas, Corinne Delcambre, Elsa Kalbacher, Antoîne Italiano, Olivier Collard,

The Lancet Oncology · 2018 · 316 citations · 32 references

DOI

Concepts

References

32

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.9K citations

, , +10

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2.1K citations · Full text

, , +9

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

, , +13

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

, , +8